Analysis of the mechanism of inhibition of liver metastasis from colon cancer ------The role of Interleukin 2 receptor of the liver sinusoidal mononuclear cells

[目的]基于肝转移癌（MLC）患者肝窦单核细胞（SMC）免疫功能受损的假设，研究了SMC和PBMC的特性。[材料与方法]采用流式细胞术对7例肝切除MLC患者的肝组织进行SMC和PBMC表面抗原的检测，其中男4例，女3例，年龄35 ~ 80岁。原发病变盲肠2例，升结肠2例，乙状结肠3例。在对照组中，我们分析了健康候选人的PBMC。MTT法检测细胞对IL-2的应答。[结果] MLC患者外周血CD 3（+）T细胞减少至30%（50-60%），SMC减少至40%（50%），NK细胞增加至25-69%（20%）。3例CEA值增高者PBMC中CD 4/CD 8比值异常，CD 8和CD 56双阳性细胞低于正常SMC（50%）的30%。IL-2 R α链被诱导，但IL-2 R β链即使在IL-2刺激后也不被识别。[结论] MLC中SMC中CTL细胞减少，尤其在CEA值较高的患者中，提示其免疫防御能力可能较正常人低。CTL对IL-2的反应性也较低。经肝动脉或门静脉注射抗肿瘤药物和IL-2的免疫化疗可能有效。该疗法可使SMC中的CTL细胞数量增加，使IL-2 R系统得到良好的调控，从而影响肝转移患者的治疗效果。

[Purpose] in this study, we studied the characters of SMC and PBMC,based on the hypothesis that the immune system managed by sinusoidal mononuclear cells (SMC) was damaged in the patient bearing metastatic liver cancer (MLC).[Materials and methods] We analyzed the surface antigens on SMC and PBMC by flowcytometry in seven liver specimens taken from hepatectomized patients with MLC.The patients were aged from 35 to 80,4males and 3 females. Primary lesions were cecum (2), ascending colon (2) and 3 sigmoid colon (3). In the control group, we analized PBMC of healthy candidates. Response against IL-2 was assesed by MTT assay.[Results] In MLC patients, CD3 (+) T cell decreased to 30 % (50-60% : normal) in PMBC and 40% (50% : normal) in SMC.CD16 (+) NK cells increased to 25-69% (20% : normal). Abnormal CD4/CD8 ratio in PBMC were observed in three cases, who showed high CEA value.CD8 and CD56 double positive cells were decresed below 30% in comparison with normal SMC (50%). IL-2R alpha chain was induced, but IL-2R beta chain was not recognized even after IL-2 stimulation.[Conclusion] In MLC,CTL cells were decreased in SMC,especially in the high CEA value patients, showng the possibility of lower immunological defense ability than normal. The lower responsiveness to IL-2 in CTL was also recognized. It may be effective that the immuno-chemothrapy by injection via hepatic artery or portal vein using anti-cancer drugs and additional IL-2. This therapy will increase the CTL cells in SMC and make a good control in IL-2 R system, affecting the excellent results for the therapy in liver metastasis patients.